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Abstract: This report describes a case of a 72-year-old Caucasian woman presenting with a 
large neurotrophic keratitis with a large persistent epithelial defect, with a longest linear diameter 
of 7 mm and greatest perpendicular width of 5 mm, affecting epithelium, Bowman membrane, 
and anterior stroma. Corneal disease was resistant to conventional treatment and classified as 
stage 2 according to Mackie classification. Patient was instructed to instill regenerating agent 
(RGTA) eye drops in the morning, as the first eye drop, once every 5 days in combination with 
daily cord blood serum (CBS) eye drops 6 times/day. The patient was asked to visit after 1 week 
(V1), 2 weeks (V2), 3 weeks (V3), and 4 weeks (V4) of study treatment. In V4 treatment, cor-
neal sensitivity improved, and keratitis healed with resolution of stromal inflammation. Global 
treatment tolerance was very satisfactory. Patient continued the therapy for a further month after 
complete healing. Currently, the patient has been followed up for 3 months without any sign of 
keratitis recurrence. To the best of our knowledge, this case report describes for the first time 
the successful combined use of RGTA and CBS eye drops for the treatment of neurotrophic 
keratitis resistant to conventional treatment. We hypothesize that RGTA eye drops could pro-
vide an optimal migration substrate and that growth factors supplied by CBS eye drops could 
strengthen the repair process by promoting cell growth over the matrix. Combined RGTA and 
CBS eye drop therapy could be a new potential option for the successful treatment of resistant 
neurotrophic keratitis, particularly when each drug alone is not effective.
Keywords: neurotrophic keratitis, regenerating agent, cord blood serum eye drops, penetrating 
keratoplasty, in vivo confocal microscopy
Background
Neurotrophic keratitis is a degenerative disease caused by damage of trigeminal innerva-
tion leading to corneal epithelial breakdown, impairment of healing and, in severe cases, 
corneal ulceration, melting, and perforation. The hallmark of this disease is a decrease or 
absence of corneal sensation.1 The trigeminal nerve provides not only corneal sensation 
but also trophic factors to the cornea, playing a key role in maintaining the anatomical 
integrity and functioning of the entire ocular surface.2 Several ocular and systemic dis-
eases can affect the trigeminal nerve at different levels. The most common causes include 
herpetic keratitis, chemical burns, physical injuries, and corneal surgery. Intracranial 
space-occupying lesions such as neuroma, meningioma, and aneurysms may also lead 
to a compression of the trigeminal nerve or ganglion and produce an impairment of cor-
neal sensitivity.3 Systemic diseases such as diabetes and multiple sclerosis may decrease 
sensory nerve function or damage sensory fibers leading to corneal hypoesthesia.4 The 





diagnosis is mainly based on the clinical history, presence of 
persistent epithelial defects or ulcers, and decreased corneal 
sensitivity. Patients rarely complain of ocular symptoms, and 
there is a significant discrepancy between clinical findings and 
subjective symptoms. A neurotrophic keratitis classification 
based on severity was proposed by Mackie, who distinguished 
three stages: epithelial alterations (stage 1), persistent epithelial 
defect (stage 2), and corneal ulcer (stage 3).5
Although the clinical diagnosis is easily oriented from 
clinical history and findings, the pharmacological manage-
ment for this disease is one of the most challenging among 
all other ophthalmological diseases. Withdrawal of all topical 
drugs is always required because they have detrimental effects 
on the ocular surface epithelium. Preservative-free artificial 
tears may improve ocular surface health at all stages of dis-
ease severity. In severe cases, the use of topical antibiotic 
eye drops is recommended to prevent infections. Steroids 
may increase the risk of corneal melting and perforation by 
inhibiting stromal healing, and their use should be considered 
with great caution. Nonsteroidal anti-inflammatory eye drops 
may inhibit the healing process and should be avoided. Sev-
eral studies, including case reports, case series, and clinical 
trials, have recently reported the efficacy of different blood-
derived eye drops in promoting neurotrophic keratitis healing 
because of their high concentrations of growth factors that 
are essential in wound healing. These products include eye 
drops obtained from autologous serum, cord blood serum 
(CBS), and platelet rich plasma.6–8 Furthermore, three 
Phase II clinical trials are currently  ongoing to evaluate the 
safety and efficacy of novel therapies for patients suffering 
from neurotrophic keratitis, including recombinant human 
nerve growth factor and regenerating agent (RGTA; Caci-
col20, OTR3, Paris, France) (ClinicalTrials.gov identifiers 
NCT02227147, NCT01756456, and NCT01794312).9–11
CBS eye drops contain biologically active components and, 
in particular, growth factors essential in corneal homeostasis 
and wound healing, and work by regulating cellular prolif-
eration, differentiation, and migration.12 CBS eye drops were 
shown to be more effective in treating severe dry eye syndrome 
compared with autologous serum eye drops.13 Furthermore, in 
vitro studies showed that RGTAs may act as survival and pro-
tective agents in several pathological tissue injuries, mimicking 
the action of destroyed heparan sulfate (HS) molecules, pro-
tecting the bioavailability of preexisting and newly synthesized 
growth factors, and recreating a matrix microenvironment in 
which cells can migrate and multiply.12,13
Taking into account these laboratory results, we hypothe-
sized a theoretical synergistic effect of RGTA and CBS eye drops 
at the site of injury and tried to translate this theory to clinical 
practice by treating, for the first time, a case of neurotrophic 
keratitis resistant to conventional therapy with a combination 
of RGTA and CBS eye drops rich in growth factors.
Case presentation
A 72-year-old Caucasian woman was referred to our 
emergency ward with progressive loss of vision in her left 
eye. The patient also observed the appearance of a wide white 
spot in the center of the cornea from a few days (Figure 1). 
About her clinical history, 6 months before she underwent 
tectonic penetrating keratoplasty in the same eye for the 
treatment of severe neurotrophic keratitis, which was the 
first clinical sign of a Gasser ganglion neuroma. The  corneal 
disease worsened after endoscopic surgical removal of 
intracranial lesion and required a first corneal transplant.
In the emergency ward, we performed complete ophthal-
mologic examination and admitted the patient to the hospital, 
prescribing systemic (meropenem intravenous) and topical 
broad-spectrum antibiotic therapy (fortified vancomycin and 
tobramycin eye drops every hour) and scheduling a second 
corneal transplant. Corneal graft melting progressed to 
perforation with iris prolapse in 2 days (Figure 2).
We performed an emergency keratoplasty (tectonic large 
diameter 11 mm penetrating) because only the extreme 
perilimbal periphery of recipient cornea was spared by the 
 melting. We used interrupted 10/0 monofilament nylon 
sutures, and the procedure was associated with iris recon-
struction, extracapsular extraction of intumescent lens, and 
chemodenervation of levator palpebrae superioris with 5 U 
of botulinum toxin type-A to induce temporary ptosis for 
corneal graft protection. Two days after surgery, the patient 
Figure 1 Corneal graft melting.
Note: Corneal graft melting observed when patient came to the emergency ward.
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was discharged from the hospital with systemic and topical 
steroids and preservative-free tear substitutes. The patient was 
visited once a week for regular checks during the postopera-
tive course. At the third postoperative month a neurotrophic 
keratitis appeared. Corneal photography at a magnification 
of ×16 showed that a large persistent epithelial defect with 
longest linear diameter equal to 7 mm, greatest perpendicular 
width equal to 5 mm, and smooth, rolled edges (Figure 3). 
No signs of ocular inflammation were present. Neurotrophic 
keratitis was classified as stage 2 according to the Mackie 
classification. Confocal microscopy analysis showed no nerve 
regeneration and stromal inflammation in the corneal graft 
(Figure 4). Corneal sensitivity measured by Cochet–Bonnet 
aesthesiometer in the standardized five regions of corneal 
graft was equal to 0 mm (length filament extrusion). The 
keratitis was sterile on microbiologic examination and did 
not improve after 4 weeks of conventional treatment, includ-
ing discontinuation of all epitheliotoxic topical medication 
and frequent (every 2 hours) instillation of preservative-free 
tear substitutes.
Taking into account previous keratoplasty failure, total 
corneal anesthesia, keratitis large size, and resistance to 
conventional treatment, we decided to prescribe RGTA in 
association with CBS eye drops. Institutional Review Board 
approval was not deemed necessary for this off label treat-
ment. However all principles outlined in the Declaration 
of Helsinki were followed. The patient was instructed to 
instill RGTA eye drops in the morning, as the first eye drop, 
once every 5 days in combination with daily CBS eye drops 
six times/day. The patient was visited after 1 week (V1), 
2 weeks (V2), 3 weeks (V3), and 4 weeks (V4) of study 
treatment. In each follow-up visit, all the aforementioned 
procedures were repeated. In detail, corneal photographies 
showed partial healing .50% already in V2 (Figure 5) and 
a complete healing in V4 (Figure 6). Confocal microscopy 
showed complete resolution of stromal inflammation in V4 
(Figure 7). Cochet–Bonnet aesthesiometry showed a mild 
improvement in V4 compared with baseline (10 mm vs 0 mm 
length filament extrusion). The mean palpebral fissure height 
of approximately 3.5 mm persisted over time during treatment 
period allowing both corneal protection and a better ocular 
surface examination compared to tarsorrhaphy. Treatment 
global tolerance assessed by both examiners and patient was 
very satisfactory. No adverse events occurred.
Figure 2 Corneal graft perforation with iris prolapse.
Note: Corneal graft melting rapidly progressed to corneal perforation with iris 
prolapse although given the systemic and topic broad-spectrum antibiotic therapy.
Figure 3 Corneal ulcer before study treatment.
Note: Corneal ulcer affected epithelium, Bowman membrane, and anterior stroma 
with a longest linear diameter equal to 7 mm and a greatest perpendicular width 
equal to 5 mm.
Figure 4 Confocal microscopy analysis of corneal ulcer before study treatment.
Note: Confocal microscopy analysis showed no nerve regeneration and stromal 
inflammation in corneal graft.





Patient continued the therapy for a further month after com-
plete healing (total treatment duration 8 weeks), after which she 
stopped and used only preservative-free tear substitutes.
Currently, the patient has been followed up for 3 months 
without any sign of keratitis recurrence. Written informed 
consent was obtained from the patient for publication of this 
case report and any accompanying images.
Discussion
Neurotrophic keratitis is a degenerative corneal disease 
caused by impairment of trigeminal innervation. Although the 
clinical diagnosis is easily oriented from the clinical history 
and findings, the pharmacological management represents 
a real therapeutic challenge for ophthalmologists, particu-
larly in patients with total corneal anesthesia as in the case 
presented earlier. Several therapeutic approaches have been 
proposed to halt the progression of the disease and to avoid 
corneal perforation. Corneal healing is a complex process 
involving cellular interaction and various molecules such as 
proteases, growth factors, and epithelial and stromal cytok-
ines. To the best of our knowledge, this case report describes 
for the first time the successful combined use of RGTA and 
CBS eye drops for the treatment of neurotrophic keratitis 
resistant to conventional treatment.
RGTAs constitute a new class of medicinal substances 
that enhance both speed and quality of tissue healing and may 
lead to a real tissue regenerating process. RGTAs consist of 
chemically engineered polymers adapted to interact with and 
protect against proteolytic degradation of cellular signaling 
proteins such as growth factors, cytokines, interleukins, 
colony-stimulating factors, chemokines, and neurotrophic 
factors. Indeed, almost all these proteins of cellular com-
munication are naturally stored in the extracellular matrix, 
interacting specifically with the HSs. After any tissue injury, 
dead cells release glycanases and proteases inducing HS 
degradation first, and subsequently, that of the cytokines, 
which are no longer protected.14,15
CBS is obtained from umbilical vein at delivery and 
contains many growth factors (epidermal growth factor, 
transforming growth factor-β, insulin-like growth factor 1, 
nerve growth factor) and essential tear components such as 
vitamin A and substance P. CBS can be used effectively 
in many ocular surface diseases, including severe dry eye 
Figure 5 Corneal ulcer after 2 weeks of study treatment (V2).
Note: Corneal ulcer improved after therapy with a partial healing .50% already in V2.
Figure 6 Corneal ulcer healing after 4 weeks of study treatment (V4).
Note: Corneal ulcer completely healed in V4.
Figure 7 Confocal microscopy analysis of the cornea after 4 weeks of study 
treatment (V4).
Note: Confocal miscroscopy showed complete resolution of stromal inflammation 
in V4.
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syndrome, persistent epithelial defects, and neurotrophic 
keratitis.12,13
The explanation for the synergistic effect of combined 
RGTA and CBS eye drops therapy originates from the 
hypothesis that in injured tissues RGTA eye drops could 
replace the natural HS and provide an optimal migration 
substrate, whereas growth factors supplied by CBS eye drops 
could strengthen the repair process by promoting cell growth 
over the regenerated matrix.
Conclusion
Neurotrophic keratitis can cause severe visual impairment 
and its treatment is very challenging for ophthalmologists. 
No therapies are currently available to restore corneal 
innervation and visual acuity. This case report describes 
for the first time the successful combined use of RGTA and 
CBS eye drops for the treatment of neurotrophic keratitis 
resistant to conventional treatment. Combined therapy with 
RGTA and CBS eye drops could be a new potential option 
for the treatment of neurotrophic keratitis, particularly when 
each drug alone is not effective. However, the findings of 
ongoing clinical trials and other translational researches from 
experimental studies are necessary to enable new potential 
therapies to treat this orphan disease.
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